Novo Nordisk A/S ($NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy.

HHS Secretary Robert F. Kennedy Jr. is proposing to strip public participation from much of the business his agency conducts

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, the growing measles outbreak in Texas,

Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the newly introduced Zepbound Self

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Eli Lilly LLY1.71%increase; green up pointing triangle is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using their health plans ...

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells.

It's hard to argue with the kinds of results Eli Lilly ( LLY 1.71%) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares leaving the broader market in the dust.

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

"Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound at Discounted Prices," at 9:33 a.m. ET, incorrectly said his surname was Johnson. About Dow Jones Newswires Dow Jones Newswires is a ...